For BRCA1 and BRCA2, breast and pancreatic cancer showed a ratio of 2:1 for germline versus somatic mutations; in ovarian and prostate cancer the ratio was 1:1, while in bladder and lung cancer, mutations were mostly of somatic origin. This evidence concerns the gene BRCA2 and prostate carcinoma.